New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
04:55 EDTCCE, CCE, CCE, IFF, IFF, IFF, WPPGY, WPPGY, WPPGY, DANOY, DANOY, DANOY, KO, KO, KO, DEO, DEO, DEO, KFT, KFT, KFT, SBMRY, SBMRY, SBMRY, CCH, CCH, CCH, PRGO, PRGO, PRGOConsumer Analyst Group of Europe to hold a conference
2014 Annual Conference of CAGE is being held in London, England on March 17-19.
News For CCE;CCH;SBMRY;KFT;DEO;KO;DANOY;WPPGY;IFF;PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 22, 2015
09:56 EDTPRGOMylan planning firmer offer for Perrigo, CNBC's Faber reports
Mylan (MYL) is planning to announce a firmer takeover offer for Perrigo (PRGO) that will include financing commitments and ticking fees, CNBC's David Faber reports, citing people familiar with the matter. It is unclear if the offer will include a higher buyout price of $205 per share, Faber added.
09:44 EDTPRGOSources: Mylan planning new offer for Perrigo, CNBC's Faber says
Subscribe for More Information
09:38 EDTKOCoca-Cola says Monster transaction now expected to close mid to late Q2
Subscribe for More Information
09:36 EDTKOCoca-Cola says productivity efforts on track across all spend areas
Subscribe for More Information
09:22 EDTKOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
08:43 EDTPRGOHostile bids carry low success rates, says Leerink
Subscribe for More Information
08:42 EDTPRGOMylan likely to seek higher offer from Teva, says Bernstein
after Teva (TEVA) offered to buy Mylan (MYL) for $82 per share, Bernstein expects Mylan to seek an offer closer to $90. The firm also expects Mylan to seek shared management and perhaps some protection for its employees. Bernstein expects Teva to attempt to convince Mylan shareholders of the merits of its offer and Mylan to attempt to convince Perrigo (PRGO) shareholders of the merits of its offer and its own shareholders of the risks associated with the Teva deal. Bernstein keeps Outperform ratings on Teva and Mylan.
08:31 EDTPRGOTeva files for Hart Scott Rodino notification regarding proposed Mylan purchase
Teva Pharmaceutical Industries (TEVA) announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion. The Teva Board and management team are committed to consummating a transaction as soon as possible. The acquisition proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry. Teva has carefully studied the regulatory aspects of a combination of Teva and Mylan, in conjunction with its advisors. Teva is confident that it would be able to structure a transaction that would not contain material impediments to closing and that it can determine and promptly implement divestitures, as necessary, to gain regulatory clearances. Teva intends to work cooperatively with antitrust authorities and expects that the proposed transaction can be completed by year-end 2015. Teva’s proposal provides Mylan stockholders with a more attractive alternative to Mylan’s proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. Barclays and Greenhill & Co. are serving as financial advisors to Teva. Kirkland & Ellis LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva, with De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V. acting as legal advisors in the Netherlands.
08:16 EDTKOCoca-Cola announces letteres of intent with U.S. bottling partners
Subscribe for More Information
07:37 EDTKOCoca-Cola up 1.8% to $41.50 in pre-market following Q1 report
07:36 EDTKOCoca-Cola CEO still sees 2015 as 'transition year'
Muhtar Kent, Chairman and CEO of The Coca-Cola Company said, "We are pleased with our solid progress on the implementation and execution of our global strategic initiatives. Though we are still in the early stages, we see some initial positive indicators that we have the right strategies in place to accelerate growth. However, we continue to view 2015 as a transition year as the benefits from the announced initiatives will take time to fully materialize amidst an uncertain and volatile macroeconomic environment. We remain committed to leveraging our superior brand portfolio together with our unparalleled global distribution system to continue creating long-term shareowner value."
07:35 EDTKOCoca-Cola reports Q1 unit case volume up 1%
Subscribe for More Information
07:34 EDTKOCoca-Cola targeting FY15 net share repurchases of $2B-$3B
Subscribe for More Information
07:34 EDTKOCoca-Cola sees 7 point headwind to revenue in Q2 from currency
For Q2, Coca-Cola estimates that currency will be an approximate 7 point headwind on net revenues, a 10 point headwind on operating income and a 5 to 6 point headwind on income before taxes.
07:33 EDTKOCoca-Cola maintains underlying FY15 currency neutral growth expectations
Coca-Cola expects full-year comparable currency neutral EPS growth to be mid single digits, roughly in line with its growth rate in 2014. FY15 EPS consensus $1.98. The company estimates that the net impact of structural items on FY15 results will be a slight headwind on net revenue growth, and it has no material changes to its prior guidance on income before taxes. The company expects fluctuations in foreign currency exchange rates to have an unfavorable impact on its reported results in 2015. Based on current spot rates, existing hedge positions, and the cycling of prior year rates, the company estimates that currency will be an approximate 6 point headwind on net revenues, a 10 point headwind on operating income, and a 7 point headwind on income before taxes for the full year.
07:31 EDTKOCoca-Cola reports Q1 comparable EPS 48c, consensus 42c
Subscribe for More Information
07:27 EDTPRGOPiper sees more sense in Teva buying Perrigo than Mylan
Piper Jaffray says that while a potential acquisition of Mylan (MYL) by Teva (TEVA) would bring major cost synergies and meaningful earnings accretion, it would not significantly improve the limited visibility on long-term top-line and earnings growth for Teva. Piper sees more strategic sense in Teva acquiring Perrigo (PRGO). Such a deal would drive multiple expansion for Teva since Perrigo's Consumer Health and Nutritionals businesses can offer a "much higher level of visibility on robust long-term earnings growth" than what Mylan can offer Teva, Piper tells investors today. The firm reiterates a Neutral rating on shares of Teva.
07:14 EDTPRGOTeva Mylan deal more likely to get done than Mylan Perrigo deal,says Wells Fargo
Subscribe for More Information
07:00 EDTPRGOPerrigo price target raised to $203 from $187 at Jefferies
Jefferies raised its price target for Perrigo (PRGO) to $203 after the company rejected Mylan's (MYL) takeover bid of $205 per share. The firm believes Perrigo "left the door wide open" for a higher, more definitive bid. It sees a 40% chance of either Mylan or another suitor acquiring Perrigo. The firm keeps a Buy rating on the stock.
06:31 EDTPRGOMylan likely to improve offer for Perrigo, says Citigroup
Citigroup believes Mylan's (MYL) board will likely reject Teva's (TEVA) initial takeover offer of $82 per share and present an improved proposal to acquire Perrigo (PRGO). Citi continues see a potential Teva-Mylan combination as more value accretive for Mylan shareholders than a potential Mylan-Perrigo combination. It keeps a Neutral rating on Mylan.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use